{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:10:18Z","timestamp":1768086618313,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China, China","doi-asserted-by":"publisher","award":["30770541"],"award-info":[{"award-number":["30770541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China, China","doi-asserted-by":"publisher","award":["81271731"],"award-info":[{"award-number":["81271731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jocn.2013.11.046","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T17:35:26Z","timestamp":1399656926000},"page":"1570-1574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action"],"prefix":"10.1016","volume":"21","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanzheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2013.11.046_b0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2013.11.046_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2013.11.046_b0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.2005.00374.x","article-title":"Myasthenia gravis: clinical, immunological, and therapeutic advances","volume":"111","author":"Romi","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2013.11.046_b0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1196\/annals.1254.032","article-title":"T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"998","author":"Milani","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2013.11.046_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/cimm.2001.1777","article-title":"Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells","volume":"208","author":"Xu","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0035","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2174\/0929867033456918","article-title":"Role of cytokines in neurological disorders","volume":"10","author":"Aarli","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jocn.2013.11.046_b0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jocn.2013.11.046_b0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2013.11.046_b0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1526-0968.2000.004004280.x","article-title":"Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience","volume":"4","author":"Qureshi","year":"2000","journal-title":"Ther Apher"},{"key":"10.1016\/j.jocn.2013.11.046_b0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1526-0968.2001.00386.x","article-title":"Plasmapheresis affects T helper type-1\/T helper type-2 balance of circulating peripheral lymphocytes","volume":"5","author":"Goto","year":"2001","journal-title":"Ther Apher"},{"key":"10.1016\/j.jocn.2013.11.046_b0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1309\/L0DG8YU2WE5DV58H","article-title":"Changes in the lymphocyte subset after double-filtration plasmapheresis","volume":"128","author":"Yeh","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jocn.2013.11.046_b0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jocn.2013.11.046_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/08916939509001933","article-title":"Titin antibodies in patients with late onset myasthenia gravis: clinical correlations","volume":"20","author":"Skeie","year":"1995","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jocn.2013.11.046_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(91)90091-K","article-title":"Anti-presynaptic membrane receptor antibodies in myasthenia gravis","volume":"102","author":"Lu","year":"1991","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2013.11.046_b0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0085","first-page":"87","article-title":"A clinical absolute and relative score system for myasthenia gravis","volume":"30","author":"Xiuyun","year":"1997","journal-title":"Chin J Neurol"},{"key":"10.1016\/j.jocn.2013.11.046_b0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1586\/ern.09.81","article-title":"Plasmapheresis for neurological disorders","volume":"9","author":"Schr\u00f6der","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jocn.2013.11.046_b0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.11.046_b0100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s004150070149","article-title":"Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis","volume":"247","author":"Yeh","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2013.11.046_b0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jocn.2013.11.046_b0110","first-page":"1165","article-title":"Plasmapheresis in patients with myasthenia gravis","volume":"66","author":"Konishi","year":"2008","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.jocn.2013.11.046_b0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand. Suppl"},{"key":"10.1016\/j.jocn.2013.11.046_b0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","article-title":"Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis","volume":"195","author":"Furukawa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2013.11.046_b0130","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0891-5849(00)00223-9","article-title":"Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades","volume":"28","author":"Hubbard","year":"2000","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jocn.2013.11.046_b0135","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.4049\/jimmunol.1100646","article-title":"ICAM-1: getting a grip on leukocyte adhesion","volume":"186","author":"Long","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0140","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1074\/jbc.272.14.9108","article-title":"Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway","volume":"272","author":"Holland","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jocn.2013.11.046_b0145","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jocn.2013.11.046_b0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejphar.2009.10.040","article-title":"Clinical implications of the type 1\/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients","volume":"627","author":"Masuda","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jocn.2013.11.046_b0155","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jocn.2013.11.046_b0160","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.2011.04547.x","article-title":"Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients?","volume":"168","author":"Jamshidian","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0170","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+ regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clim.2007.12.010","article-title":"CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids","volume":"127","author":"Azab","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jocn.2013.11.046_b0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2249.2010.04183.x","article-title":"The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins","volume":"161","author":"Sewgobind","year":"2010","journal-title":"Clin Exp Immunol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:04:34Z","timestamp":1648983874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586814001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0967586814001131"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2013.11.046","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2013.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}